Document is current
Any future updates will be listed below
-
Authors
Qin, Yaning
Liang, Zhiqi
Yu, Mengqin
Lin, Nanqian
Wang, Naizhen
Huang, Xuanke
Chen, Shi
Peng, Qun
Lin, Yanhua
Wang, Heqin
Rao, Yipeng
Xu, Zilong https://orcid.org/0009-0001-5619-5834
Huang, Shenghua
Cai, Jingjing
Li, Yukui
Zhang, Jun https://orcid.org/0000-0002-6601-9180
Lin, Chaolong https://orcid.org/0009-0005-5284-4533
Tan, Guowei
Xia, Ningshao https://orcid.org/0000-0003-0179-5266
Huang, Chenghao https://orcid.org/0000-0001-8267-1307
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82373286)
National Science and Technology Major Project
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 19 February 2026
First Online: 28 February 2026
Competing interests
: C.H., M.Y., Y.Q., Y.L., J.Z., and N.X. are inventors on patent application submitted by Xiamen University that covers the concept of combining LRRK2 inhibitors and OVs for cancer therapy (Application No. 202310157529.3). The other authors declare no competing interest.
